NewAmsterdam Pharma Company N.V.NAMSNASDAQ
Loading
Price to Sales: Premium ValuationElevated
Percentile Rank100
3Y CAGR+345.8%
Year-over-Year Change
Price-to-sales ratio
3Y CAGR
+345.8%/yr
Annual compound
Percentile
P100
Near historical high
vs 3Y Ago
88.6x
Strong expansion
Streak
1 yr
Consecutive growthElevated
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 178.34 | +235.1% |
| 2024 | 53.22 | -18.3% |
| 2023 | 65.13 | +3135.5% |
| 2022 | 2.01 | - |
| 2021 | 0.00 | - |
| 2020 | 0.00 | - |